• Je něco špatně v tomto záznamu ?

Rationale and design of the ELEANOR trial early aortic valve surgery versus watchful waiting strategy in severe asymptomatic aortic regurgitation, ACRONYM: ELEANOR

R. Kočková, J. Vojáček, H. Bedáňová, P. Fila, I. Skalský, D. Žáková, M. Klán, B. Míková, K. Mědílek, M. Tuna, M. Fialová, R. Dvořáková, Z. Hlubocká, R. Panovský, K. Slabý, E. Kelen de Oliveira, F. Casselman, M. Pěnička

. 2024 ; 10 (8) : e29470. [pub] 20240409

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24012895

BACKGROUND: The optimal treatment of patients with severe symptomatic aortic regurgitation (AR) is state-of-the-art surgery. Asymptomatic patients with advanced left ventricular (LV) dilatation and/or impaired ejection fraction should undergo surgical treatment, but there is no guidelines consensus on cut-off values for this recommendation. Multimodality imaging has brought new tools for the accurate selection of asymptomatic patients at risk of early clinical deterioration, however, prospective and randomized data are pending. Cardiac magnetic resonance (CMR)-derived AR quantification along with LV remodeling assessment appears to be the most accurate tool for a selection of such patients at risk. TRIAL DESIGN: The objective of our prospective and multicenter study is to determine whether patients at risk of early clinical deterioration as per CMR assessment will benefit from early surgical treatment. The study is designed as a superiority trial to demonstrate that early surgical treatment is safe and more effective than the standard treatment. A total of 217 asymptomatic patients with severe AR, but without current guidelines-based surgical indication, will be enrolled across all centers. We expect 24 % of patients identified as high clinical risk and therefore eligible for 1:1 randomization to early surgical treatment within 3 months or a watchful waiting strategy. Follow-up will be annual. We expect a complete restoration of LV size and function along with improved quality of life and physical performance in a short-term follow-up of 12 months. The primary endpoint will be a composite safety and efficacy with all criteria mandatory: 15 % or larger reduction of baseline CMR-derived LV end-diastolic volume index, LV ejection fraction >50 %, and no major adverse cardiovascular events. The annual follow-up will continue for a minimum of 4 years until the required number of endpoints is achieved to show a statistically significant difference in cardiovascular morbidity and mortality in early surgically treated patients. CONCLUSION: The ELEANOR trial is the first multicenter randomized controlled study to compare early surgical treatment with a watchful waiting strategy in asymptomatic patients with chronic severe AR at high risk of early clinical deterioration as per CMR assessment but without guidelines-based indications for surgical treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012895
003      
CZ-PrNML
005      
20240726151437.0
007      
ta
008      
240723s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.heliyon.2024.e29470 $2 doi
035    __
$a (PubMed)38638969
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kočková, Radka $u Na Homolce Hospital, Prague, Czech Republic $u Charles University, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic
245    10
$a Rationale and design of the ELEANOR trial early aortic valve surgery versus watchful waiting strategy in severe asymptomatic aortic regurgitation, ACRONYM: ELEANOR / $c R. Kočková, J. Vojáček, H. Bedáňová, P. Fila, I. Skalský, D. Žáková, M. Klán, B. Míková, K. Mědílek, M. Tuna, M. Fialová, R. Dvořáková, Z. Hlubocká, R. Panovský, K. Slabý, E. Kelen de Oliveira, F. Casselman, M. Pěnička
520    9_
$a BACKGROUND: The optimal treatment of patients with severe symptomatic aortic regurgitation (AR) is state-of-the-art surgery. Asymptomatic patients with advanced left ventricular (LV) dilatation and/or impaired ejection fraction should undergo surgical treatment, but there is no guidelines consensus on cut-off values for this recommendation. Multimodality imaging has brought new tools for the accurate selection of asymptomatic patients at risk of early clinical deterioration, however, prospective and randomized data are pending. Cardiac magnetic resonance (CMR)-derived AR quantification along with LV remodeling assessment appears to be the most accurate tool for a selection of such patients at risk. TRIAL DESIGN: The objective of our prospective and multicenter study is to determine whether patients at risk of early clinical deterioration as per CMR assessment will benefit from early surgical treatment. The study is designed as a superiority trial to demonstrate that early surgical treatment is safe and more effective than the standard treatment. A total of 217 asymptomatic patients with severe AR, but without current guidelines-based surgical indication, will be enrolled across all centers. We expect 24 % of patients identified as high clinical risk and therefore eligible for 1:1 randomization to early surgical treatment within 3 months or a watchful waiting strategy. Follow-up will be annual. We expect a complete restoration of LV size and function along with improved quality of life and physical performance in a short-term follow-up of 12 months. The primary endpoint will be a composite safety and efficacy with all criteria mandatory: 15 % or larger reduction of baseline CMR-derived LV end-diastolic volume index, LV ejection fraction >50 %, and no major adverse cardiovascular events. The annual follow-up will continue for a minimum of 4 years until the required number of endpoints is achieved to show a statistically significant difference in cardiovascular morbidity and mortality in early surgically treated patients. CONCLUSION: The ELEANOR trial is the first multicenter randomized controlled study to compare early surgical treatment with a watchful waiting strategy in asymptomatic patients with chronic severe AR at high risk of early clinical deterioration as per CMR assessment but without guidelines-based indications for surgical treatment.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vojáček, Jan $u Charles University, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic $u University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Bedáňová, Helena $u Centre of Cardiovascular Surgery and Transplantation, Brno, Czech Republic
700    1_
$a Fila, Petr $u Centre of Cardiovascular Surgery and Transplantation, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Skalský, Ivo $u Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Žáková, Daniela $u Centre of Cardiovascular Surgery and Transplantation, Brno, Czech Republic
700    1_
$a Klán, Michal $u Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Míková, Barbora $u Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Mědílek, Karel $u Charles University, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic $u University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Tuna, Martin $u Charles University, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic $u University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Fialová, Monika $u University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Dvořáková, Radka $u University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Hlubocká, Zuzana $u 2nd Department of Internal Cardiovascular Medicine, General University Hospital in Prague, First Faculty of Medicine, Charles University, Czech Republic
700    1_
$a Panovský, Roman $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic $u 1st Department of Internal, Brno, Czech Republic Medicine/Cardioangiology at St. Anne's University Hospital, Brno, Czech Republic
700    1_
$a Slabý, Kryštof $u Department of Rehabilitation and Sports Medicine, Second Faculty of Medicine, Charles University in Prague, Czech Republic
700    1_
$a Kelen de Oliveira, Elayne $u CardioPaTh PhD Program, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy $u Cardiovascular Center OLV Clinic Aalst, Belgium
700    1_
$a Casselman, Filip $u Cardiovascular Center OLV Clinic Aalst, Belgium
700    1_
$a Pěnička, Martin $u Cardiovascular Center OLV Clinic Aalst, Belgium
773    0_
$w MED00190064 $t Heliyon $x 2405-8440 $g Roč. 10, č. 8 (2024), s. e29470
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38638969 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151429 $b ABA008
999    __
$a ok $b bmc $g 2125511 $s 1224758
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 10 $c 8 $d e29470 $e 20240409 $i 2405-8440 $m Heliyon $n Heliyon $x MED00190064
LZP    __
$a Pubmed-20240723

Najít záznam

Citační ukazatele

Možnosti archivace